# 2026-01305: DEA Eyes Opioid Bulk Maker for Tiny Research Batches: Speak Now

2026-01305, Bulk Manufacturer of Controlled Substances Application: Organic Consultants LLC DBA Cascade Chemistry, is a Federal Register notice from Justice Department, Drug Enforcement Administration published 2026-01-23, effective 2026-03-24 (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-01305
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-01305
- Title: Bulk Manufacturer of Controlled Substances Application: Organic Consultants LLC DBA Cascade Chemistry
- Type: Notice
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 91 FR 2962
- Published: 2026-01-23
- Effective: 2026-03-24
- Comments close: 2026-03-24
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

DEA Eyes Opioid Bulk Maker for Tiny Research Batches: Speak Now

## Summary

Organic Consultants LLC, also known as Cascade Chemistry, wants to become a big-time maker of certain controlled drugs like codeine and oxycodone. They plan to produce small amounts mainly for testing and research. If you have thoughts or objections, you’ve got until March 24, 2026, to speak up online—no cost involved!

## Abstract

Organic Consultants, LLC DBA Cascade Chemistry has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-20749](https://policyrisk.com/federal-register/2026-20749): Vladimir Romaniv, P.A.; Decision and Order, 2026-10-09
- [2026-20750](https://policyrisk.com/federal-register/2026-20750): L Krenk DBA Maui Clinic Pharmacy; Decision and Order, 2026-10-09

## Sources
- [2026-01305 on federalregister.gov](https://www.federalregister.gov/documents/2026/01/23/2026-01305/bulk-manufacturer-of-controlled-substances-application-organic-consultants-llc-dba-cascade-chemistry)
- [2026-01305 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-01-23/pdf/2026-01305.pdf)

## Related
- [Previous: 2026-01298, Bulk Manufacturer of Controlled Substances Application: Maridose LLC](https://policyrisk.com/federal-register/2026-01298)
- [Next: 2026-01306, Agency Information Collection Activities; Submission for OMB Review; Comment Re…](https://policyrisk.com/federal-register/2026-01306)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-01305 (as of 2026-06-08).